Zymeworks Stock Price, News & Analysis

Jazz Pharmaceuticals has secured exclusive rights to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody, from Zymeworks in major markets including the U.S., Europe, and Japan. Zymeworks will receive an upfront payment of $50 million, with the potential for total payments reaching $1.76 billion upon meeting various milestones. Zanidatamab, currently in pivotal trials for HER2-expressing biliary tract cancer and gastroesophageal adenocarcinoma, has received Breakthrough Therapy designation from the FDA, underscoring its potential in oncology.

Zymeworks Inc. (NYSE: ZYME) will report its third quarter 2022 financial results on November 8, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing insights into financial results and corporate updates. The company specializes in developing multifunctional biotherapeutics, with its lead candidate, zanidatamab, in various clinical trials targeting HER2 in solid tumors. Zymeworks is advancing other candidates including ZW49, a bispecific HER2-targeted antibody-drug conjugate currently in Phase 1.

Zymeworks Inc. (NYSE: ZYME) has completed its Redomicile Transactions, transitioning to a Delaware corporation. This move allows New Zymeworks to assume all assets and liabilities of the previous British Columbia entity. Shareholders of the former parent company will receive either Delaware Common Stock or exchangeable shares. Trading of the new stock commenced on October 13, 2022. Zymeworks is focused on developing multifunctional biotherapeutics, with its leading candidate, zanidatamab, undergoing several pivotal clinical trials globally for HER2-expressing solid tumors.

Zymeworks Inc. (NYSE: ZYME) announced the successful approval from its securityholders to redomicile as a Delaware corporation during a special meeting held on October 7, 2022. A total of 34,612,420 votes supported the decision, representing 94.84% of those present. This move aims to expand the investor base and streamline commercialization efforts for their lead product, zanidatamab, and other candidates. The company will provide further details on the outcome of the special meeting in subsequent filings.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, announced participation in several upcoming investor conferences. Management will present at the Stifel 2022 Healthcare Conference in New York from November 15-16 and the Jefferies London Healthcare Conference from November 15-17. An Early R&D Day is scheduled for October 20, 2022, in New York, featuring updates on preclinical research from Chief Scientific Officer Paul Moore, PhD. Presentations will be accessible on Zymeworks' website.

Zymeworks Inc. (NYSE: ZYME) presented preliminary results from its Phase 1 clinical trial of zanidatamab zovodotin (ZW49) targeting HER2-positive tumors at the ESMO 2022 Congress. Seventy-seven patients were enrolled to assess safety, tolerability, and anti-tumor activity. The maximum tolerated dose remains undetermined, but results show a 31% confirmed objective response rate and a 72% disease control rate with a manageable safety profile. The trial continues, with results from an alternate dosing regimen expected in 2023.

Zymeworks Inc. is proceeding with a proposed redomicile to Delaware, aiming to enhance long-term value for securityholders and improve growth prospects. The special meeting of securityholders is set for October 7, 2022, to vote on this resolution. If approved, common shares of Zymeworks will convert to shares in the newly formed New Zymeworks. The company anticipates this move may increase institutional investor interest and align it with peers in the biotechnology sector.

Zymeworks Inc. (NYSE: ZYME) announced preliminary results from its Phase 1 study of zanidatamab zovodotin (ZW49), a bispecific HER2-targeted antibody-drug conjugate, at the ESMO Congress 2022. The study involved 76 patients with HER2+ cancers, revealing a manageable safety profile and encouraging anti-tumor activity. Notably, the confirmed objective response rate was 28%, with a disease control rate of 72%. Most treatment-related adverse events were manageable, and no treatment-related deaths were reported. Further data will be presented by Dr. Komal Jhaveri on September 12.